Budget impact (BI) analysis of cemiplimab for first-line (1L) advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% in the United States.

e18817Background: Cemiplimab monotherapy (mono) demonstrated significant survival benefit versus chemotherapy (CT) in the first-line (1L) treatment of advanced NSCLC with PD-L1 ≥50%. This analysis ...